Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 7989020, 8 pages
https://doi.org/10.1155/2017/7989020
Research Article

Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers

1Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar
2College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
3Institute of Cancer Sciences, University of Manchester, Manchester, UK

Correspondence should be addressed to Eyad Elkord

Received 3 September 2017; Accepted 4 October 2017; Published 5 November 2017

Academic Editor: Jian Song

Copyright © 2017 Salman M. Toor and Eyad Elkord. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Global Burden of Disease Cancer Collaboration, C. Fitzmaurice, C. Allen et al., “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study,” JAMA Oncology, vol. 3, no. 4, pp. 524–548, 2017. View at Publisher · View at Google Scholar
  2. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Toor and E. Elkord, “Myeloid-derived suppressor cells,” eLS, pp. 1–8, 2015. View at Publisher · View at Google Scholar
  4. S. M. Toor, A. S. Syed Khaja, H. El Salhat et al., “Increased levels of circulating and tumor-infiltrating granulocytic myeloid cells in colorectal cancer patients,” Frontiers in Immunology, vol. 7, p. 560, 2016. View at Publisher · View at Google Scholar
  5. S. M. Toor, A. S. Syed Khaja, H. El Salhat et al., “Myeloid cells in circulation and tumor microenvironment of breast cancer patients,” Cancer Immunology, Immunotherapy, vol. 66, no. 6, pp. 753–764, 2017. View at Publisher · View at Google Scholar
  6. A. S. Syed Khaja, S. M. Toor, H. El Salhat, B. R. Ali, and E. Elkord, “Intratumoral FoxP3+Helios+ regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer,” Frontiers in Immunology, vol. 8, p. 619, 2017. View at Publisher · View at Google Scholar
  7. A. S. Syed Khaja, S. M. Toor, H. El Salhat et al., “Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment,” Oncotarget, vol. 8, no. 20, pp. 33159–33171, 2017. View at Publisher · View at Google Scholar
  8. D. Hanahan and L. M. Coussens, “Accessories to the crime: functions of cells recruited to the tumor microenvironment,” Cancer Cell, vol. 21, no. 3, pp. 309–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Angell and J. Galon, “From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer,” Current Opinion in Immunology, vol. 25, no. 2, pp. 261–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Vignali and M. Kallikourdis, “Improving homing in T cell therapy,” Cytokine & Growth Factor Reviews, vol. 36, pp. 107–116, 2017. View at Publisher · View at Google Scholar
  11. J. Zhou, S. S. Donatelli, D. L. Gilvary et al., “Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin,” Scientific Reports, vol. 6, p. 29521, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. G. J. Guthrie, K. A. Charles, C. S. Roxburgh, P. G. Horgan, D. C. McMillan, and S. J. Clarke, “The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer,” Critical Reviews in Oncology/Hematology, vol. 88, no. 1, pp. 218–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ohki, M. Shibata, K. Gonda et al., “Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer,” Oncology Reports, vol. 28, no. 2, pp. 453–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Bronte, S. Brandau, S. H. Chen et al., “Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards,” Nature Communications, vol. 7, p. 12150, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. K. McPherson, C. M. Steel, and J. M. Dixon, “ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics,” BMJ, vol. 321, no. 7261, pp. 624–628, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Terzic, S. Grivennikov, E. Karin, and M. Karin, “Inflammation and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101–2114.e5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Diaz-Montero, M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero, “Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy,” Cancer Immunology, Immunotherapy, vol. 58, no. 1, pp. 49–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Y. OuYang, X. J. Wu, S. B. Ye et al., “Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer,” Journal of Translational Medicine, vol. 13, no. 1, p. 47, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. H. L. Sun, X. Zhou, Y. F. Xue et al., “Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma,” World Journal of Gastroenterology, vol. 18, no. 25, pp. 3303–3309, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Zhang, Z. Wang, L. Wu et al., “Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma,” PLoS One, vol. 8, no. 2, article e57114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Moses and S. Brandau, “Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells,” Seminars in Immunology, vol. 28, no. 2, pp. 187–196, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ostrand-Rosenberg, “Immune surveillance: a balance between protumor and antitumor immunity,” Current Opinion in Genetics & Development, vol. 18, no. 1, pp. 11–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Palucka and J. Banchereau, “Cancer immunotherapy via dendritic cells,” Nature Reviews Cancer, vol. 12, no. 4, pp. 265–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. B. Sims, “Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer,” Vaccine, vol. 30, no. 29, pp. 4394–4397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. L. J. Eggermont, L. E. Paulis, J. Tel, and C. G. Figdor, “Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells,” Trends in Biotechnology, vol. 32, no. 9, pp. 456–465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. K. L. Flannigan, D. Geem, A. Harusato, and T. L. Denning, “Intestinal antigen-presenting cells: key regulators of immune homeostasis and inflammation,” The American Journal of Pathology, vol. 185, no. 7, pp. 1809–1819, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. M. L. Broz, M. Binnewies, B. Boldajipour et al., “Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity,” Cancer Cell, vol. 26, no. 5, pp. 638–652, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Cowherd, “Tumor staging and grading: a primer,” Methods in Molecular Biology, vol. 823, pp. 1–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Derwinger, K. Kodeda, E. Bexe-Lindskog, and H. Taflin, “Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer,” Acta Oncologica, vol. 49, no. 1, pp. 57–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. A. Rakha, J. S. Reis-Filho, F. Baehner et al., “Breast cancer prognostic classification in the molecular era: the role of histological grade,” Breast Cancer Research, vol. 12, no. 4, p. 207, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Cavallo, C. de Giovanni, P. Nanni, G. Forni, and P. L. Lollini, “2011: the immune hallmarks of cancer,” Cancer Immunology, Immunotherapy, vol. 60, no. 3, pp. 319–326, 2011. View at Publisher · View at Google Scholar · View at Scopus